The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies.

abstract：:Sequencing of the gene encoding for von Willebrand factor (VWF) has brought new insight into the physiology of VWF as well as its pathophysiology in the context of von Willebrand disease (VWD). Molecular testing in VWD patients has shown high variability in the overall genetic background of this condition. Almost 600 ...

journal_title：Seminars in thrombosis and hemostasis

authors： Zolkova J,Sokol J,Simurda T,Vadelova L,Snahnicanova Z,Loderer D,Dobrotova M,Ivankova J,Skornova I,Lasabova Z,Kubisz P,Stasko J

更新日期：2020-06-01 00:00:00

abstract：:Patients treated with oral anticoagulants (OAC) carry a 7- to 10-fold higher risk of intracerebral hemorrhage (ICH) than patients without OAC. ICH related to oral anticoagulation (OAC-ICH) is a particularly severe form of stroke. The overall incidence of OAC-ICH ranges between 2 and 9 per 100,000 population/year and i...

journal_title：Seminars in thrombosis and hemostasis

authors： Veltkamp R,Rizos T,Horstmann S

更新日期：2013-11-01 00:00:00

abstract：:The identification of the JAK2 V617F mutation in patients with myeloproliferative disorders (MPDs) represents a major breakthrough in our understanding of the pathogenesis of these diseases. One year after its discovery, an impressive number of publications appeared. These articles confirmed most of the initial result...

journal_title：Seminars in thrombosis and hemostasis

authors： Villeval JL,James C,Pisani DF,Casadevall N,Vainchenker W

更新日期：2006-06-01 00:00:00

abstract：:Fibrin formed from fibrinogen is the main component of thrombi. Clot structure is characterized by fiber thickness and pore size, which differs within a given clot and between individuals. Plasma clot architecture is largely determined by the quantity and quality of fibrinogen. Plasma fibrinogen concentrations are mos...

journal_title：Seminars in thrombosis and hemostasis

authors： Undas A

更新日期：2016-06-01 00:00:00

abstract：:Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities. Plasma is treated with solvent-detergent to disrupt enveloped viruses, or with photoactive agents methylene blue plus ligh...

journal_title：Seminars in thrombosis and hemostasis

authors： Ramsey G

更新日期：2016-03-01 00:00:00

abstract：:The three-dimensional structures of several forms of the factor XIII A subunit have been determined using single crystal x-ray diffraction methods. Our crystallographic studies have provided the first detailed structural view of the factor XIII A subunit and information that is useful for understanding transglutaminas...

journal_title：Seminars in thrombosis and hemostasis

authors： Yee VC,Le Trong I,Bishop PD,Pedersen LC,Stenkamp RE,Teller DC

更新日期：1996-01-01 00:00:00

abstract：:Heparin is a familiar anticoagulant drug with properties that may impede tumor growth; it modifies properties of cells that contribute to malignant dissemination such as angiogenesis, growth factor and protease activity, immune function, proliferation, and gene expression. Heparin has antitumor effects in animal model...

journal_title：Seminars in thrombosis and hemostasis

authors： Zacharski LR,Ornstein DL,Mamourian AC

更新日期：2000-01-01 00:00:00

abstract：:Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Jonge E,van der Poll T,Kesecioglu J,Levi M

更新日期：2001-12-01 00:00:00

abstract：:Severe trauma is the leading cause of death globally. Though improved resuscitation, particularly early initiation, has reduced the 24-hour mortality rate, the overall morbidity and 30-day mortality remain high mostly due to massive hemorrhage and head injury in the early stages and sepsis and multiorgan failure later...

journal_title：Seminars in thrombosis and hemostasis

authors： Kwaan HC

更新日期：2020-03-01 00:00:00

abstract：:Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and i...

journal_title：Seminars in thrombosis and hemostasis

authors： Falanga A,Marchetti M

更新日期：2014-04-01 00:00:00

abstract：:The increased prevalence of the laboratory diagnosis of von Willebrand disease (vWD) in women presenting with menorrhagia has raised concerns regarding certain specifics in vWD testing in women, including when vWD testing should be done in relation to menses and whether testing should be done while the patient is not ...

journal_title：Seminars in thrombosis and hemostasis

authors： Kouides PA

更新日期：2006-07-01 00:00:00

abstract：:The present study revises the criteria of the Polycythemia Vera Group (PVSG) for the diagnoses of essential thrombocythemia (ET) and polycythemia vera (PV) in view of accumulating data on in vitro cultures of hematopoietic progenitors and by adding histopathology from bone marrow biopsies. The majority of ET patients ...

journal_title：Seminars in thrombosis and hemostasis

authors： Michiels JJ,Juvonen E

更新日期：1997-01-01 00:00:00

abstract：:The contribution of platelet dysfunction to the impaired hemostasis after cardiac surgery remains to be established, because there is no sensitive method to assess platelet function. Measurement of the shear-induced pathway of platelet function, an important mechanism in inducing hemostasis, became possible by a novel...

journal_title：Seminars in thrombosis and hemostasis

authors： Tabuchi N,Tigchelaar I,van Oeveren W

更新日期：1995-01-01 00:00:00

abstract：:From injury through healing, thrombin has several important functions in blood clotting, subsequent clot lysis, and tissue repair. These include edema, inflammation, cell recruitment, cellular releases, transformations, mitogenesis, and angiogenesis. Thrombin also participates in disease states, such as venous thrombo...

journal_title：Seminars in thrombosis and hemostasis

authors： Fenton JW 2nd,Ofosu FA,Brezniak DV,Hassouna HI

更新日期：1998-01-01 00:00:00

abstract：:Congenital amegakaryocytic thrombocytopenia (CAMT, MIM #604498) is a rare inherited bone marrow failure syndrome presenting as isolated hypomegakaryocytic thrombocytopenia at birth without other characteristic physical anomalies. Most of the patients develop a severe aplastic anemia and trilineage cytopenia during the...

journal_title：Seminars in thrombosis and hemostasis

authors： Ballmaier M,Germeshausen M

更新日期：2011-09-01 00:00:00

abstract：:Coagulation factor XII (FXII), formerly known as Hageman factor, is a plasma glycoprotein which exerts a kaleidoscope of biological functions, including the initiation of the intrinsic pathway of blood coagulation, the activation of the kallikrein-kinin system, and the generation of bradykinin and angiotensin. The lar...

journal_title：Seminars in thrombosis and hemostasis

authors： Danese E,Montagnana M,Lippi G

更新日期：2016-09-01 00:00:00

abstract：:To elucidate the mechanisms by which hematopoietic progenitor cells selectively lodge in bone marrow, we established endothelial cell lines derived from bone marrow and lung and then examined the transendothelial migration of hematopoietic progenitor cells by using cells was examined by a Transwell migration assay. He...

journal_title：Seminars in thrombosis and hemostasis

authors： Imai K,Kobayashi M

更新日期：1998-01-01 00:00:00

abstract：:Rheological alterations are commonly found in malignant disease and are most pronounced in advanced-stage cancer. Although most of these changes are caused by cancer-unspecific mechanisms, it has been shown that the extent of these changes in some cancer types is related with the stage of cancer, prognosis of disease,...

journal_title：Seminars in thrombosis and hemostasis

authors： von Tempelhoff GF,Heilmann L,Hommel G,Pollow K

更新日期：2003-10-01 00:00:00

abstract：:Bleeding can be a serious complication of surgery, and topical thrombin is widely used as an adjunct to hemostasis in diverse surgical settings. The potent hemostatic properties of thrombin derive from its ability to activate platelets directly to aggregate and adhere to damaged vessels and to catalyze the formation s...

journal_title：Seminars in thrombosis and hemostasis

authors： Bishop PD,Lewis KB,Schultz J,Walker KM

更新日期：2006-04-01 00:00:00

abstract：:Polycystic ovarian syndrome (PCOS) affects 12 to 19% of women and has reproductive and metabolic features (endothelial dysfunction, increased diabetes, and cardiovascular risk factors). It also appears to have altered coagulation and fibrinolysis with a prothrombotic state with epidemiological evidence of increased ve...

journal_title：Seminars in thrombosis and hemostasis

authors： Burchall GF,Piva TJ,Linden MD,Gibson-Helm ME,Ranasinha S,Teede HJ

更新日期：2016-02-01 00:00:00

abstract：:Platelets have classically been considered crucial effector cells in hemostasis, but now are increasingly recognized as players during inflammatory responses in innate and adaptive immunity. Platelets can recognize and kill invading pathogens, and, upon stimulation, also release a wide array of mediators that modify i...

journal_title：Seminars in thrombosis and hemostasis

authors： Kim SJ,Davis RP,Jenne CN

更新日期：2018-03-01 00:00:00

abstract：:Unfractionated heparin and LMMH were substituted with different lipophilic organic compounds. Specifically endpoint attached (LMMH-tyramine and LMMH-tyramine-FITC) and nonspecifically substituted heparins (acylated heparins, and LMMH-biotin and LMMH-cholesterol hemisuccinate) were obtained. The lipophilically substitu...

journal_title：Seminars in thrombosis and hemostasis

authors： Malsch R,Harenberg J,Guerrini M,Torri G,Casu B,Heene DL

更新日期：1994-01-01 00:00:00

abstract：:Hemophilia A (HA) and hemophilia B (HB) are rare congenital severe bleeding disorders, that may be controlled by proper administration of adequate prophylaxis with factor VIII (FVIII), and factor IX (FIX) concentrates, respectively, to prevent joint damage due to recurrent bleeding. However, approximately 30% of patie...

journal_title：Seminars in thrombosis and hemostasis

authors： Barg AA,Livnat T,Kenet G

更新日期：2018-09-01 00:00:00

abstract：:The survival rate of children with cancer has increased impressively to almost 80% over the last decades as a result of improved diagnostic procedures and multimodal treatment strategies. Therefore, it becomes more and more important to prevent mortality and morbidity of treatment-associated complications, including v...

journal_title：Seminars in thrombosis and hemostasis

authors： van Ommen CH,Chan AK

更新日期：2014-04-01 00:00:00

abstract：:The molecular basis for the hereditary type I protein S (PS) deficiency was investigated. DNA sequence analysis of 12 patients with PS deficiency in Japan identified four point mutations and three of them were novel. Nonsense mutations found in two unrelated patients resulted in termination of the PS polypeptide chain...

journal_title：Seminars in thrombosis and hemostasis

authors： Iwaki T,Mastushita T,Kobayashi T,Yamamoto Y,Nomura Y,Kagami K,Nakayama T,Sugiura I,Kojima T,Takamatsu J,Kanayama N,Saito H

更新日期：2001-01-01 00:00:00

abstract：:In the Netherlands, specialized care for patients with a bleeding disorder, including hemophilia, von Willebrand disease (VWD), and allied disorders, is concentrated in 13 Hemophilia Treatment Centers. The Dutch Hemophilia Treaters Society, the Dutch Hemophilia Nurses' Society, and the Netherlands Hemophilia Patients ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Wee EM,Leebeek FW,Eikenboom JC

更新日期：2011-07-01 00:00:00

abstract：:Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to approximately 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. Ho...

journal_title：Seminars in thrombosis and hemostasis

authors： Lee CA,Lillicrap D,Astermark J

更新日期：2006-06-01 00:00:00

abstract：:Through in depth studies, the biochemical pathways of hemostasis-related systems have been elucidated in terms of well-defined molecular mechanisms. The interrelationships of coagulation, fibrinolytic, kallikrein-kinin, platelets, prostaglandins, blood vessel, and complement systems are now well understood. Methods ar...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Bick RL,Bermes EJ Jr,Messmore HL Jr

更新日期：1983-10-01 00:00:00

abstract：:APC resistance is often associated with the occurrence of a single point mutation in factor V (factor VLeiden) at a predominant cleavage site for the natural anticoagulant, activated protein C (APC). In this article we will discuss the effects of this mutation (Arg506-->Gln) on the down-regulation of factor Va cofacto...

journal_title：Seminars in thrombosis and hemostasis

authors： Rosing J,Hemker HC,Tans G

更新日期：1998-01-01 00:00:00

abstract：:Each bone marrow megakaryocyte (MK) releases thousands of platelets into the circulation, and the underlying molecular and cellular mechanisms recently have received intense scrutiny. Genetic studies are beginning to clarify the mechanisms by which transcription factors help distinguish MK progenitors from other blood...

journal_title：Seminars in thrombosis and hemostasis

authors： Schulze H,Shivdasani RA

更新日期：2004-08-01 00:00:00